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Purpose: This study was conducted to determine how frequently self-reported 
symptoms are captured as adverse drug events (ADEs) during chart abstraction. 
Method: We studied Ontario Cohort Study (OCS) participants attending the Toronto 
Hospital Immunodeficiency Clinic and compared OCS data on ADEs collected semi-
annually through chart review and a self-administered questionnaire, completed on 
up to three occasions, which asked about the frequency, severity, and chronicity of 
symptoms including diarrhea, nausea, fatigue, and changes in body shape. Among 
64 participants who completed the questionnaires, the median age was 42 years, 
the median time since HIV diagnosis was 9 years, 84% were male, 58% were men 
who had sex with men, 70% had viral load levels below 50 copies/mL, and the me-
dian CD4 was 422 cells/mm3. All patients were taking antiretroviral therapy. Results: 
The median (interquartile range) number of symptoms per participant reported on 
the questionnaire at the first visit was 3 (1–5). The most common symptoms reported 
by patients were diarrhea (58%), headache (59%), difficulty sleeping (52%), dry skin 
(53%), and changes in body shape (52%). The median number of ADEs during the 
study period per participant in OCS was 1 (0–2). Of 345 symptoms identified on 
the questionnaire, 16% were reported as ADEs in the OCS. Conclusion: Although 
some symptoms were correctly not classified as ADEs as they were not related to 
antiretroviral medication, others may have been missed due to incomplete reporting 
to the physician, incomplete physician recording, or errors in chart extraction. Key 
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mong people with HIV infection, antiretrovi-
ral-related adverse drug events (ADEs), such 
as gastrointestinal side effects, lipodystrophy, 
lipid abnormalities, and cardiovascular outcomes, 
are increasingly concerning. Cohort studies indi-
cate that 36% to 50% of people living with HIV ex-
perience one or more adverse drug events (ADEs) 
attributable to antiretroviral therapy and up to 10% 
to 16% of these reactions are serious or severe.1–4 
An even larger percentage of patients experience 
symptoms, if we consider both symptoms that are 
a  result  of  antiretroviral  therapy  and  those  due 
to HIV and its complications.5 Symptoms are an 
important area of study because of the associated 
discomfort and because such symptoms may result 
not only in reduced adherence to medications and 
concern for drug resistance or treatment failure but 
also permanent discontinuation of drugs that can 
limit therapeutic options. Recent data suggest that 
symptoms occurring after initiation of ART are the 
most common reason that individuals discontinue 
HAART in the first year of treatment.2,6 Symptoms 312	 HIV	ClInICal	TrIals	 •	 8/5	 •	 sepT-OCT	2007
can also result in significant costs associated with 
additional physician visits,7 further medication to 
alleviate the symptoms, and tests to determine the 
etiology of the symptom as well as costs related to 
HIV complications that could result from interrup-
tion or discontinuation of ART.
Although randomized trials are the gold stan-
dard  for  estimating  treatment  effects,  they  are 
often not powered to estimate rates of ADEs that 
occur  rarely,  only  after  a  significant  exposure  to 
the treatment, or only in subgroups of patients. For 
such ADEs, observational studies of large popula-
tions over prolonged periods may present superior 
research  designs.8  Two  strategies  for  obtaining 
observational data on ADEs are chart reviews and 
self-administered  questionnaires.  Extraction  of 
symptom data from charts may be inconsistent and 
incomplete due to failure of the patient to convey 
appropriate information to the clinician, failure of 
the clinician to adequately document the severity 
and frequency of the adverse event and its relation-
ship to medication,9 or failure of the chart abstrac-
tor to correctly interpret the medical record.10 Even 
though self-administered questionnaires may be a 
good tool for measuring symptom burden, they are 
costly and less reliable for recording ADEs because 
patients may be uncertain as to whether or not the 
symptom is a result of the antiretroviral therapy. 
The  design  of  self-administered  questionnaires 
must  strike  a  careful  balance  between  enough 
questions to describe the symptoms in sufficient 
detail and too many questions that might overtax 
participants.
This  study  was  conducted  to  determine  how 
much  of  the  symptom  burden  as  reported  on  a 
self-administered questionnaire was captured by 
extracting data on ADEs from patient charts.
METHOD
We used two data sources for our study. The first, 
the  Ontario  Cohort  Study  (OCS),  is  a  voluntary 
cohort study of more than 3,400 HIV-infected indi-
viduals receiving health care in Ontario, Canada, 
that records a broad range of information includ-
ing clinical events, medication use, and laboratory 
results. The second data source was a self-adminis-
tered questionnaire filled out by patients attending 
the Toronto Hospital Immunodeficiency Clinic. All 
patients attending the clinic from October 2002 to 
July  2004  who  were  OCS  enrollees  were  invited 
to  participate  in  the  study.  Ethics  approval  was 
obtained from the University Health Network, of 
which Toronto General Hospital is a member.
Ontario Cohort Study
The  OCS  recruits  participants  from  HIV  spe-
cialty  and  primary  care  clinics  throughout  the 
province of Ontario. More than 3,400 individuals 
have enrolled in OCS since 1994 and have ongoing 
data collection. As of December 2005, there were 
660  OCS  participants  from  the  Toronto  Hospital 
Immunodeficiency Clinic site, of which 296 were 
currently  active  patients.  OCS  participants  com-
plete a self-administered questionnaire at enroll-
ment  pertaining  to  demographic  data  and  HIV 
testing and exposure history. All participants con-
sented to have trained data extractors review their 
medical charts and extract detailed clinical, labo-
ratory,  and  medication  information.  Information 
is  recorded  about  adverse  events  believed  to  be 
related to medication for their HIV disease. ADEs 
are recorded using an open (spontaneous) model 
in which neither individuals nor data collectors are 
restricted in the type of ADE they may report, how-
ever, symptoms not specifically noted to be related 
to study medication are not recorded as adverse 
events. The OCS study is administered by the On-
tario HIV Treatment Network, an independently 
incorporated,  not-for-profit  organization  funded 
by the AIDS Bureau, Ontario Ministry of Health 
and Long-Term Care. OCS received research ethics 
approval from the University of Toronto as well as 
from the ethics boards of several hospitals where 
patients were enrolled.
Of the 991 active patients in the Toronto Hospital 
Immunodeficiency Clinic, 296 are OCS enrollees. 
Compared to the general clinic population at the 
Toronto Hospital Immunodeficiency Clinic, those 
who are enrolled in OCS are more likely to be male, 
men having sex with men (MSM), older, currently 
receiving protease inhibitors (PIs) and non-nucleo-
side reverse transcriptase inhibitors (NNRTIs), and 
less likely to have immigrated to Canada in the 
past 5 years.
Questionnaire
The self-administered questionnaire asked about 
fever,  fatigue,  headache,  nausea,  vomiting,  diar-
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fusion, kidney stones, numbness of hands or feet, 
dry skin or lips or ingrown toenails, and changes 
in body shape within the past 3 months. This list 
was composed of symptoms attributable to anti-
retroviral therapy but not tailored to the specific 
patient  regimen.  The  WHO-ART,11  ACTG,12  and 
HIV Swiss Cohort2 adverse event lists were used 
as  models  in  developing  our  questionnaire.  For 
each symptom, participants were asked about the 
severity, frequency, and chronicity of the symptom 
but not the likelihood that a symptom was a result 
of medication taken. Chronicity of a symptom was 
classified as not within the past 3 months, ongoing 
problems with the symptom, or only within the past 
3  months.  Frequency  of  the  symptom  within  the 
previous 3 months was classified as infrequent (<7 
days), a few days (7–13 days), often (14–40 days), and 
frequent (>40 days). Classification of the severity of 
symptoms varied according to symptoms and was 
based on the AIDS Clinical Trials Group (ACTG) 
classification. We intended to survey participants 
on  three  occasions  (baseline,  3  months,  and  6 
months), but the number and timing of surveys 
varied somewhat. Patients completed the question-
naire before their visit with their physician.
ADE, demographic, and medication data were 
extracted from the OCS database for individuals 
who had completed at least one questionnaire. The 
frequency and types of symptoms reported on the 
questionnaires  were  compared  to  the  ADE  data 
extracted from OCS.
Statistical Methods
Demographic  and  clinical  characteristics  were 
summarized  with  numbers  and  proportions  for 
categorical variables and medians and interquar-
tile ranges for continuous variables. The numbers 
and proportions of patients experiencing a symp-
tom at each visit and at any of the three visits were 
tabulated. The proportions of symptoms that were 
captured as ADEs in the OCS were tabulated by 
type of symptom, severity of symptom, frequency 
of symptom, and chronicity of symptom. The Co-
chran-Armitage test for trend was used to examine 
relationships  between  ordered  categorical  vari-
ables and the probability of a symptom being cap-
tured as an adverse event.13 Adverse events with an 
onset date after the date of the last questionnaire or 
with a resolution date more than 90 days before the 
first questionnaire were excluded. Because the date 
of resolution of an ADE was not available for ap-
proximately two thirds of ADEs recorded in OCS, 
it was difficult to determine whether those ADEs 
occurred during the 3 months prior to administra-
tion of the questionnaire. Thus, ADEs from OCS 
with onset dates before the last questionnaire and 
with missing resolution dates were assumed to be 
ongoing during the study period. This strategy is 
likely to result in an overestimate of the proportion 
of symptoms that were recorded in OCS as adverse 
events.
RESULTS
A total of 64 participants filled out the question-
naire: 33 on three occasions, 21 on two occasions, 
and 10 on one occasion. The median numbers of 
months  between  the  first  and  second  visit  and 
between the second and third visits were 5.5 (inter-
quartile range [IQR] 3.2–9.0) and 4.9 (IQR 3.4–8.4), 
respectively.  Of  the  31  patients  who  completed 
fewer  than  three  questionnaires,  6  were  lost  to 
follow-up and 25 continued to be followed in the 
clinic  but  declined  to  participate  further  in  the 
study.
The  majority  of  participants  were  male  (84%), 
with a median age of 42 years (Table 1). The major 
self-identified risk factors for HIV infection were 
MSM  (58%)  and  heterosexual  sex  (42%).  Partici-
pants were generally healthy, with 70% having a 
viral load less than or equal to 50 copies/mL at the 
first visit and a median CD4 count of 423 cells/
mm3. At the first visit, 95% of the participants were 
taking nucleoside reverse transcriptase inhibitors 
(NRTIs), 64% were taking PIs, and 45% were tak-
ing NNRTIs.
The  median  number  of  symptoms  reported 
at the first, second, and third visits were 3 (IQR 
1–5,  range  0–13),  3.5  (IQR  1–7,  range  0–11),  and 
4.0 (IQR 2–7, range 0–11). The median number of 
symptoms per visit of patients who completed one 
or two questionnaires was 3 (IQR 1–5), compared 
to a median of 4 (IQR 2–8) among patients who 
completed three questionnaires (p = .15), indicat-
ing that patients who completed more visits had 
similar  numbers  of  symptoms.  In  general,  indi-
viduals were consistent in the level of reporting 
of symptoms across visits. Nine individuals (14%) 
did  not  report  any  symptoms  during  the  study 
period, 9 individuals (14%) reported one or two 
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ongoing.  Among  patients  reporting  a  symptom, 
the symptoms most commonly described as severe 
were changes in body shape (21%), fatigue (19%), 
numbness in hands and feet (18%), and difficulty 
sleeping (18%). Among patients reporting a symp-
tom, the symptoms most commonly described as 
occurring frequently (40+ days in past 3 months) 
were dry skin (41%), nausea (30%), difficulty sleep-
ing (29%), diarrhea (28%), and numbness of hands 
and feet (27%).
Of the 225 adverse events reported in OCS at 
any time period for these patients, 98 (48%) of the 
records  noted  adverse  events,  comorbidities,  or 
abnormal laboratory results that were not asked 
about  in  the  questionnaire;  10  were  duplicate 
events; and 30 ADEs were resolved at least 90 days 
before the date of the first questionnaire or com-
menced after the date the last questionnaire was 
completed. A total of 87 adverse events remained 
in the comparative analysis between the question-
naires and the OCS database. The OCS database 
did not capture any information about severity or 
frequency of the adverse events, and the duration 
of the event was inconsistently recorded.
Of  345  symptoms  that  were  reported  in  the 
questionnaire, 57 (16%) were captured as adverse 
events in the OCS (Table 3). The symptoms most 
likely  to  be  captured  in  the  OCS  were  diarrhea 
(38%), nausea (35%), and changes in body shape 
(27%). The symptoms least likely to be recorded 
in OCS as ADEs were confusion (0%) and dry skin 
(0%). The frequency of a symptom was not associ-
ated with an increased likelihood that the event 
was recorded in OCS as an ADE (chi-square test for 
trend, p = .34). Severe symptoms were only slightly 
more likely than moderate or mild symptoms to be 
reported in OCS (21% vs. 19% and 15%) (Table 3). 
Of the 47 severe symptoms reported in the ques-
tionnaires, only 10 were recorded in OCS as ADEs. 
The 37 severe symptoms that were not recorded 
in OCS were lipodystrophy (6), headache (6), dif-
ficulty sleeping (4), fatigue (5), numbness in hands 
or feet (5), dry skin (3), nausea (2), vomiting (2), 
diarrhea (2), rash (1), and fever (1). A retrospective 
chart review of the 37 symptoms not recorded in 
OCS revealed that 10 (27%) were not mentioned in 
the chart at all, 5 (14%) were in the chart but not in 
OCS and presumably thought to be drug related, 
and 22 (59%) were in the chart but no indication of 
being drug related and thus were not adverse drug 
events.
Table 1.  Characteristics of study population at first 
visit (N = 64)
Characteristic
Age, years; median (IQR) 42 (37–47)
Gender, male; n (%) 54 (84%)
Risk factor for acquiring HIVa, n (%)
  Men who have sex with men 37 (58%)
  Injection drug user 2 (3%)
  Heterosexual transmission 27 (42%)
  Other 1 (2%)
Years since diagnosis, median (IQR)b 9 (3–13)
Viral load less than 50 copies/mL 45 (70%)
CD4 count cells/mm3, median (IQR) 423 (254–636)
Medication use at first visitc
  Nucleoside reverse transcriptase 
inhibitor
61/64 (95%)
  Non-nucleoside reverse 
transcriptase inhibitor
29/64 (45%)
  Protease inhibitor 41/64 (64%)
Note: IQR = interquartile range.
aIndividuals may have more than one risk factor.
bYears since diagnosis to first visit.
cIndividuals may be taking more than one class of medica-
tions.
five symptoms, and 26 individuals (41%) reported 
six or more symptoms during the study period. 
Reporting of individual symptoms was less con-
sistent, with mild events often starting or resolving 
and other events changing in frequency or severity. 
Eighty-five percent of patients reported at least one 
symptom at each of the three visits. The percentage 
of patients who reported at least one symptom that 
had appeared in the last 3 months varied between 
30% and 46% at the three visits. The median num-
bers of ongoing symptoms and recent onset symp-
toms, per person per visit, were 2 (IQR 0– 5) and 0 
(IQR 0–1), respectively.
Symptoms were summarized over visits by re-
cording the worst severity, chronicity, frequency, 
and presence reported during the three visits for 
each patient (Table 2). The most common symp-
toms  were  diarrhea  (58%),  headache  (59%),  dif-
ficulty sleeping (52%), dry skin (53%), and changes 
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Table 2.  Presence, chronicity, severity, and frequency of adverse events as reported in questionnaire
Adverse 




Yes 33 (52) Ongoing 27 (82) LOSS (face, arms, legs, 
buttocks)
Mild (noticeable only to 
self)
  4 (28)
Recent 
onset
  6 (18) Moderate (noticeable to 
others – friends)
18 (64)
Severe (noticeable to 
strangers)
  6 (21)
GAIN (abdominal, 
shoulders)
Mild (noticeable only to 
self)
10 (50)
Moderate (noticeable to 
others – friends)
  6 (30)
Severe (noticeable to 
strangers)
  4 (20)
No 30 (48)
Confusion Yes 18 (29) Ongoing 14 (78) Mild (lasted a short time)   9 (50) Infrequentlyc   8 (44)
Recent 
onset
  4 (22) Moderate (lasted longer 
but did not interfere 
with daily activities)
  9 (50) A few days   4 (22)
Severe (interfered with 
daily activities)
  0 Often   4 (22)
Frequently   2 (11)
No 45 (71)
Diarrhea Yes 37 (58) Ongoing 29 (78)  Mild (3–4 loose stools per 
day)
25 (71) Infrequently   7 (19)
Recent 
onset
  8 (22) Moderate (5–7 loose 
stools per day)
  5 (14) A few days   8 (22)
Severe (more than 7 
loose stools/day)
  5 (14) Often 11 (31)
Frequently 10 (28)
No 27 (42)
Fatigue Yes 27 (42) Ongoing 24 (89) Reduced some activities 13 (50) Infrequently   4 (15)
Recent 
onset
  3 (11) Reduced many activities   8 (31) A few days   9 (35)
Reduced most of 
activities
  5 (19) Often   8 (31)
Frequently   5 (19)
No 37 (58)
Fever Yes 18 (29) Ongoing   7 (39) Mild (100–101.5ºF)   9 (56) Infrequently 10 (63)
Recent 
onset
11 (61) Moderate (101.6–102.9ºF)   6 (38) A few days   2 (12)
Severe (103+ºF)   1 (6) Often   2 (12)
Frequently   2 (12)
No 45 (71)
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Table 2.  Continued
Adverse 
event Present n (%) Chronicitya nb (%) Severity nb (%) Frequency  nb (%)
Numbness 
hand/feet
Yes 28 (44) Ongoing 23 (82) Mild (not interfering with 
function)
15 (54) Infrequently   8 (31)
Recent 
onset 
  5 (18) Moderate (interfering with 
function but not daily 
activities)
  8 (29) A few days   5 (19)
Severe (interfering with 
daily activities)
  5 (18) Often   6 (23)
Frequently   7 (27)
No 36 (56)
Headache Yes 38 (59) Ongoing 26 (76) Mild (no medication) 12 (32) Infrequently 19 (53)
Recent 
onset
  8 (24) Moderate (over the 
counter medication)
19 (51) A few days   7 (19)
Severe (prescription 
medication)
  6 (16) Often   9 (22)




Yes 29 (46) Ongoing 25 (86) Mild (did not impact daily 
activities)
18 (62) Infrequently   5 (17)
Recent 
onset
  4 (14) Moderate (required 
therapy)
  9 (31) A few days   8 (28)
Severe (severe anxiety or 
depression)
  2 (7) Often 13 (45)
Frequently   3 (10)
No 34 (54)
Nausea Yes 23 (36) Ongoing 17 (74) Mild (eating almost 
normally)
10 (43) Infrequently   7 (30)
Recent 
onset
  5 (26) Moderate (reduced food 
intake)
11 (48) A few days   5 (22)
Severe (very reduced 
food intake)
  2 (9) Often   4 (18)
Frequently   7 (30)
No 41 (64)
Rash Yes 11 (17) Ongoing   6 (60) Mild (redness/itchy skin)   7 (64) Infrequently   1 (9)
Recent 
onset
  4 (40) Moderate (causes 
significant discomfort)
  3 (27) A few days   2 (18)
Severe (blistering, covers 
most of body)
  1 (9) Often   6 (55)
Frequently   2 (18)
No 53 (83)
Dry skin Yes 34 (53) Ongoing 29 (91) Mild (manages with 
moisturizers)
21 (61) Infrequently   4 (13)
Recent 
onset
  3 (9) Moderate (not managed 
with moisturizers or 
mild steroid cream)
10 (29) A few days   7 (22)
Severe (responds poorly 
to powerful steroid 
cream)
  3 (9) Often   8 (25)
Frequently 13 (41)
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Table 2.  Continued
Adverse 






Yes 33 (52) Ongoing 28 (85) Mild (no medication) 10 (30) Infrequently   5 (16)
Recent 
onset
  5 (15) Moderate (minimal 
medication)
17 (52) A few days   4 (13)
Severe (not lessened by 
medication)
  6 (18) Often 13 (42)
Frequently   9 (29)
No 31 (48)
Vomiting Yes 14 (22) Ongoing   8 (57) Mild (2–3 episodes per 
day)
  9 (75) Infrequently   6 (43)
Recent 
onset
  6 (43) Moderate (4–5 episodes 
per day)
  1 (8) A few days   6 (43)
Severe (all foods and 
fluids)
  2 (17) Often   1 (7)




Yes    3 (5) Ongoing   3 (100) Mild   1 (50) Infrequently   2 (66)
Moderate   1 (50) A few days   0 (0)
Severe   0 (0) Often    1 (33)
Frequently   0 (0)
No 61 (95)
aRecent onset means that the adverse drug event (ADE) appeared in the past 3 months.
bNumbers in subcategories may not always add up to the number of symptoms present due to missing data on chronicity, sever-
ity, and frequency.
cInfrequently (less than 7 days in past 3 months), a few days (7–15 days in past 3 months), often (14–40 days in past 3 months), 
frequently (40+ days in past 3 months).
Of the 87 ADEs reported in the OCS, 56 were 
reported on the questionnaires and 31 were not: 
rash  (6),  difficulty  sleeping  (5),  mood  (4),  nau-
sea  (4),  diarrhea  (4),  vomiting  (3),  numbness  in 
hands and feet (2), headache (1), fatigue (1), and 
changes in body shape (1). Because the OCS data 
covered  a  wider  time  frame  than  the  question-
naire, these symptoms may not have been bother-
some to the patient at the time they completed the 
questionnaire.
DISCUSSION
We compared self-administered symptom ques-
tionnaires to ADE data extracted from charts. Our 
principal  finding  was  that,  among  HIV-infected 
patients receiving antiretroviral therapy, only one 
in six self-reported symptoms was abstracted as 
an ADE. Although  low,  this  proportion  is  likely 
an overestimate, because the time frame for chart 
extraction was wider than the reporting period for 
symptoms in the questionnaire.
Our findings should be interpreted with some 
caution, because we were comparing data collected 
for  different  purposes.  The  questionnaire  asked 
patients to report their experience with a list of 14 
symptoms, whether or not they were believed to be 
related to HIV medications; in contrast, chart ab-
straction only collected symptoms believed to have 
a relationship to current HIV medication. Further-
more, some symptoms have known relationships 
to  therapy,  such  as  lipodystrophy,  while  others 
may  have  multiple  etiologies,  such  as  difficulty 
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prevalent and commonly associated with antiret-
roviral medication, such as body changes, nausea, 
and diarrhea, were only recorded in one quarter 
to one third of OCS ADE records, suggesting that 
chart  abstraction  may  miss  many  important  pa-
tient-related outcomes.
Several explanations might account for missing 
ADE data in the OCS. Patients may tend to report 
a symptom in response to a prompt more readily 
than to volunteer it independently or to not have 
reported all symptoms to their physician due to 
forgetfulness, resolution of the symptom, or a de-
sire to optimize the physician visit to deal with an-
other issue. Physicians may also have incompletely 
recorded  a  symptom  because  it  was  previously 
documented, not thought to be important, or not 
thought to be drug related. Last, the chart abstrac-
tor may have overlooked some events in the data 
extraction process.
Although the frequency of incomplete recording 
varied from symptom to symptom, no symptoms 
were  recorded  in  the  chart  as ADEs  more  often 
than reported on the questionnaire as symptoms. 
Some symptoms in particular, such as confusion, 
dry skin, and fever, were very poorly captured by 
OCS. A full four fifths of severe symptoms reported 
on questionnaires were not captured as ADEs in 
OCS. Almost two thirds of these severe symptoms 
were noted in the chart but not recorded in the 
database  because  they  were  not  related  to  HIV 
medication, one quarter of the events were not re-
corded in the chart at all, and the remainder were 
not recorded in the database even though noted 
in  the  chart.  Although  some  improvements  in 
rates of reporting of symptoms can be achieved by 
improved chart abstraction procedures and more 
careful  discussion  of  symptoms  between  patient 
and  physician,  the  most  important  gain  would 
be  made  through  focusing  on  collecting  data  in 
the  database  on  symptoms  rather  than  ADEs  if 
clinicians and researchers want to fully describe 
patients’  experiences.  Further,  because  the  link 
between symptoms and drugs may not always be 
clear for unrecognized toxicities, focusing only on 
ADEs  may  underestimate  the  effects  associated 
with newer medications.
Our  results  agree  with  those  of  other  studies, 
which have also demonstrated poor agreement of 
patient and provider reports and underreporting 
of symptoms and of symptom severity by provid-
ers as compared to patients in both HIV-infected 
Table  3.  Proportions  of  symptoms  reported  in 
questionnaire that are captured as adverse events 
in chart abstractions by type of event, severity, and 
frequency
Adverse event n (%)
Type of event







Numbness hand/feet 5/28 (18)
Headache 4/38 (11)
Changes in mood 1/29 (3)
Nausea 8/23 (35)
Rash 2/11 (18)
Dry skin 0/34 (0)
Difficulty sleeping 7/33 (21)
Vomiting 3/14 (21)
Kidney stones 1/3 (33)






  Total 61/359 (17)
Frequency
Infrequent 8/84 (9.5)




  Total 47/311 (15)
Chronicity
Recent onset 8/66 (12)
Ongoing 38/236 (16)
Unknown 1/9 (11)
  Total 47/311 (15)
Note: The numbers of events in the classification by severity 
are larger than the numbers of events classified by frequency 
or presence total because the changes in body shape were 
counted  twice  for  classifications  by  severity,  once  for  loss 
events,  and  once  for  gain  events.  “Frequency”  was  not  re-
corded for “changes in body shape,” thus the total number 
of events by frequency is less than the total number of events 
by type of event. All records for changes in body shape are 
removed for chronicity; the questionnaire did not distinguish 
between loss and gain events and whether they had separate 
onsets.	 prOpOrTIOn	Of	sympTOms	CapTured	as	ades	 •	 rabOud	eT	al.	 319
individuals14–16 and in other patient populations.9,17 
A  20-item  self-completed  HIV  symptom  index 
has  been  developed  in  an  effort  to  standardize 
reporting and improve completeness of symptom 
documentation.18
Limitations of our study include the small sam-
ple size, the single site involved in the study, and 
the  fact  that  we  have  not  formally  assessed  the 
reliability or validity of our questionnaire. Despite 
this, we believe our findings demonstrate that da-
tabases dependent on chart abstraction of adverse 
events as a data collection tool are likely to signifi-
cantly underreport patients’ symptom burdens. We 
recommend  implementation  of  symptom  check-
lists in clinical settings to improve the quality of 
data for research purposes, but a full assessment of 
feasibility, including data quality, and cost remain 
outstanding.
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